Nonmelanomatous Skin Cancer - Pipeline Review, H1 2014

Date: June 15, 2014
Pages: 45
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N01D99F757CEN
Leaflet:

Download PDF Leaflet

Nonmelanomatous Skin Cancer - Pipeline Review, H1 2014
Summary

Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Pipeline Review, H1 2014’, provides an overview of the Nonmelanomatous Skin Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Nonmelanomatous Skin Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Nonmelanomatous Skin Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Nonmelanomatous Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Nonmelanomatous Skin Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Nonmelanomatous Skin Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Nonmelanomatous Skin Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Nonmelanomatous Skin Cancer Overview
Therapeutics Development
Pipeline Products for Nonmelanomatous Skin Cancer - Overview
Pipeline Products for Nonmelanomatous Skin Cancer - Comparative Analysis
Nonmelanomatous Skin Cancer - Therapeutics under Development by Companies
Nonmelanomatous Skin Cancer - Therapeutics under Investigation by Universities/Institutes
Nonmelanomatous Skin Cancer - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Nonmelanomatous Skin Cancer - Products under Development by Companies
Nonmelanomatous Skin Cancer - Products under Investigation by Universities/Institutes
Nonmelanomatous Skin Cancer - Companies Involved in Therapeutics Development
LEO Pharma A/S
Genextra S.p.a.
Advancell
Biosceptre International Limited
Nonmelanomatous Skin Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DAC-0060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dz-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibody Targeting P2RX7 for Nonmelanomatous Skin Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANs-40 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OXT-328 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANS-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANS-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for HPV Associated Skin Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNA Repair Polypeptides - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ingenol Mebutate Analogs for Dermatology and Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nonmelanomatous Skin Cancer - Recent Pipeline Updates
Nonmelanomatous Skin Cancer - Dormant Projects
Nonmelanomatous Skin Cancer - Discontinued Products
Nonmelanomatous Skin Cancer - Product Development Milestones
Featured News & Press Releases
Aug 27, 2004: Initiation Of Human Trials
Jun 29, 2004: INDs for Peplin’s Lead Product Filed with FDA
Nov 25, 2002: Allergan In-Licenses A Compound For The Treatment Of Non-Melanoma Skin Cancers From Peplin Biotech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Nonmelanomatous Skin Cancer, H1 2014
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Investigation by Universities/Institutes, H1 2014
Nonmelanomatous Skin Cancer - Pipeline by LEO Pharma A/S, H1 2014
Nonmelanomatous Skin Cancer - Pipeline by Genextra S.p.a., H1 2014
Nonmelanomatous Skin Cancer - Pipeline by Advancell, H1 2014
Nonmelanomatous Skin Cancer - Pipeline by Biosceptre International Limited, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Nonmelanomatous Skin Cancer Therapeutics - Recent Pipeline Updates, H1 2014
Nonmelanomatous Skin Cancer - Dormant Projects, H1 2014
Nonmelanomatous Skin Cancer - Discontinued Products, H1 2014

LIST OF FIGURES

Number of Products under Development for Nonmelanomatous Skin Cancer, H1 2014
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

COMPANIES MENTIONED
LEO Pharma A/S
Genextra S.p.a.
Advancell
Biosceptre International Limited
Peritoneal Cancer - Pipeline Review, H1 2014 US$ 2,000.00 Feb, 2014 · 218 pages
Rectal Cancer - Pipeline Review, H1 2014 US$ 2,000.00 Feb, 2014 · 88 pages
Colorectal Cancer - Pipeline Review, H1 2014 US$ 2,000.00 May, 2014 · 613 pages
Ovarian Cancer - Pipeline Review, H1 2014 US$ 2,500.00 Apr, 2014 · 1076 pages
Uterine Cancer - Pipeline Review, H1 2014 US$ 2,000.00 Apr, 2014 · 50 pages

Ask Your Question

Nonmelanomatous Skin Cancer - Pipeline Review, H1 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: